- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
New System Targets Germs in Donated Blood Plasma
A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.
The Intercept Blood System for plasma targets germs including AIDS-causing HIV, hepatitis B and C, and the West Nile virus, the FDA said in a news release.
The system uses controlled exposure to ultraviolet light and a germ-targeting chemical called amotosalen, the agency said. The plasma is then purified to remove the chemical and any byproducts.
While the system has proven effective, no system or device has been shown to eliminate all germs. The Intercept system hasn’t been effective, for example, in eliminating the human parvovirus B19 and spores formed by certain bacteria, the FDA said.
The system’s clinical safety and effectiveness were evaluated in studies involving more than 700 people.
Side effects were comparable to those among people who received untreated plasma, the agency said.
The Intercept system is marketed by Cerus Corp., based in Concord, Calif.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.